Gilead Sciences | BiotechTV

top of page

ASCO 2025: Gilead Sciences' Chairman & CEO Dan O'Day discusses today's 'practice changing' data for Trodelvy in 1L triple-negative breast cancer, cell therapy, and more from the oncology pipeline

He discusses the result of the ASCENT-04 study, which was in combination with Keytruda in PD-L1+ patients, and highlights data...

Company News

May 31

Gilead's Dan O'Day on 1Q23 Earnings

BiotechTV's exclusive interview with Gilead Sciences' Chairman & CEO Dan O'Day on the company's Q1 2023 earnings day.

Company News

Apr 26, 2023

Kite Pharma's Kristi Shaw talks cell therapy at #JPM23

Kite’s Kristi Shaw discusses BCMA, moving CAR-T into earlier lines of treatment, and focusing on improving auto programs.

Company News

Jan 10, 2023

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

Learn more about Evaluate

bottom of page

ASCO 2025: Gilead Sciences' Chairman & CEO Dan O'Day discusses today's 'practice changing' data for Trodelvy in 1L triple-negative breast cancer, cell therapy, and more from the oncology pipeline

Gilead's Dan O'Day on 1Q23 Earnings

Kite Pharma's Kristi Shaw talks cell therapy at #JPM23

Follow BiotechTV

Sponsors

Sponsor Spotlight